Jpmorgan Chase & Co »

Aligos Therapeutics shares owned by Jpmorgan Chase & Co

Quarter-by-quarter ownership of Aligos Therapeutics shares owned by Jpmorgan Chase & Co from 13F filings

Historical chart of Jpmorgan Chase & Co investment in Aligos Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aligos Therapeutics held by Jpmorgan Chase & Co consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aligos Therapeutics by Jpmorgan Chase & Co

Quarter filed Position value Share count Share price at filing
2024-09-30 $224 26 8.65

More positions owned by Jpmorgan Chase & Co

Microsoft Corp Common (MSFT)
Nvidia Corporation Common (NVDA)
Apple Common (AAPL)
Amazon Common (AMZN)
Spdr S&p 500 Etf Ser 1 S&p Common (SPY)
Meta Platforms Common (META)
Eli Lilly & Co Common (LLY)
Alphabet Common (GOOG)
Unitedhealth Group Common (UNH)
Mastercard Incorporated Common (MA)
Vanguard Index Fds S&p 500 Etf Common (VOO)
Ishares Core S&p 500 Etf Fund (IVV)
Vanguard Total Intl Bond Etf Fund (BNDX)
Broadcom Common (AVGO)
Exxon Mobil Corp Common (XOM)

View all positions for Jpmorgan Chase & Co

Top funds holding Aligos Therapeutics

Woodline Partners
Baker Bros. Advisors
Hillhouse Capital Advisors
Acadian Asset Management
Geode Capital Management
Renaissance Technologies
Charles Schwab Investment Management
BlackRock
Bank of America Corporation
CWM
Advisor Group Holdings
AlphaMark Advisors
Jpmorgan Chase & Co
Zrc Wealth Management
Bnp Paribas Arbitrage, Snc

View all funds holding Aligos Therapeutics